BigOmics raises $1.85M to revolutionise omics data analytics

BigOmics is a Swiss startup that democratises biodata analysis to accelerate scientific discoveries in medicine thanks to its interactive and user-friendly platforms designed for life scientists. This capital injection will allow the company to expand its team and commercialise its solutions.

Currently incubated at USI Startup Centre, BigOmics is a spin-off of the Institute of Oncology Research (IOR, affiliated to Università della Svizzera italiana) in Bellinzona, and the Dalle Molle Institute for Artificial Intelligence (IDSIA, joint institute of USI and SUPSI). With its solution, BioTech & Pharma companies and academic labs in the field of data-driven therapeutics and precision medicine can significantly reduce data analysis time and costs. 

BigOmics’ self-service analytics platforms for omics data empower life scientists with powerful but easy-to-use interactive dashboards so that they can explore and analyse their data themselves, reducing the workload of bioinformaticians and significantly accelerating the discovery process. It is a win-win proposition for biologists and bioinformaticians that balances data quality and analysis agility. Omics Playground is BigOmics’ flagship platform for visualising and analysing transcriptomics and proteomics data types. To date, more than 16,000 users accessed the platform, and the startup has closed enterprise subscriptions with three BioTech & Pharma companies and two academic labs. 

BigOmics raised $1.42 million on the first closing of its pre-series A round in October 2021 after graduating from the US-based Alchemist Accelerator. The round, coordinated by TiVentures with the participation of Century Oak Capital, Champion Hill Ventures and Acequia Capital, comes on top of the $430,000 funding raised earlier this year in a seed round from TiVentures and ADM Partners. Business angels Raul Vejar and Mark Jalabert, as well as Nathan Kaiser from the Swiss ICT Investor Club (SICTIC) network, also joined the round. The pre-series A remains open until January 2022 for additional funding. 

Murodzhon Akhmedov (CEO and Co-Founder) said: “We are excited to have been supported by dynamic VCs and angels in this new financing round in our mission to solve the omics data analysis bottleneck. This funding will enable us to expand our team and to actively commercialise our platform solutions.” Ivo Kwee (CTO and Co-Founder) added: “The closing of this first part of pre-series A funding will allow us to further support the development of our platforms and improve product-market-fit. We want to build the smoothest and most user-friendly platforms for omics data with a world-class team.”